Lineage-Specific Epigenomic and Genomic Activation of Oncogene HNF4A Promotes Gastrointestinal Adenocarcinomas

Abstract

Gastrointestinal adenocarcinomas (GIAC) of the tubular GI tract including esophagus, stomach, colon, and rectum comprise most GI cancers and share a spectrum of genomic features. However, the unified epigenomic changes specific to GIAC are poorly characterized. Using 907 GIAC samples from The Cancer Genome Atlas, we applied mathematical algorithms to large-scale DNA methylome and transcriptome profiles to reconstruct transcription factor (TF) networks and identify a list of functionally hyperactive master regulator (MR) TF shared across different GIAC. The top candidate HNF4A exhibited prominent genomic and epigenomic activation in a GIAC-specific manner. A complex interplay between the HNF4A promoter and three distal enhancer elements was coordinated by GIAC-specific MRTF including ELF3, GATA4, GATA6 and KLF5; HNF4A also self-regulated its own promoter and enhancers. Functionally, HNF4A promoted cancer proliferation and survival by transcriptional activation of many downstream targets, including HNF1A and factors of Interleukin signaling, in a lineage-specific manner. Overall, our study provides new insights into the GIAC-specific gene regulatory networks and identifies potential therapeutic strategies against these common cancers. Statement of significance: Findings show that GIAC-specific master regulatory transcription factors control HNF4A via three distal enhancers to promote GIAC cell proliferation and survival. Research.

FOXE1 Gene Dosage Affects Thyroid Cancer Histology and Differentiation In Vivo

“…According to these evidences, our in vivo model shows that lower FOXE1 expression leads to the development of less differentiated cancers, which display lower proliferation and higher apoptosis rates, thereby strengthening the possibility that FOXE1 could exert contrasting roles in thyroid neoplastic transformation. Based on these evidences, we might speculate that FOXE1 could act as a lineage-specific oncogene [18][19][20][21], meaning that it governs lineage proliferation and survival during development as well as promoting oncogenic phenotypes in cells of the same lineage during carcinogenesis.…”

BRD4 PROTAC degrader ARV-825 inhibits T-cell acute lymphoblastic leukemia by targeting 'Undruggable' Myc-pathway genes

“…ChIP was performed as described previously [ 24 ]. Briefly, 3–5 × 10 7 cells were crosslinked with 1% formaldehyde for 10 min and neutralized with 1.25 M glycine for 5 min at room temperature.…”

Widespread reorganisation of the regulatory chromatin landscape facilitates resistance to inhibition of oncogenic ERBB2 signalling

“…6P). This set of transcription factors has previously been shown to be operational in both Barrett’s and OAC (Rogerson et al, 2019, 2020; Chen et al, 2020; Ma et al, 2021; Pan et al, 2020) and suggests that ERBB2 activation leads to at least partial suppression of their activity in OAC cells. Alternatively, additional compensatory pathways may be activated in response to drug treatment which further enhance the activity of this set of transcription factors.…”

“…Opening regions showed enrichment of motifs for a range of transcription factors which drive a gastro-intestinal programme in OAC including HNF4, GATA, FOXA, KLF and CEBP factors after 35 days (Fig. 4B; Supplementary Table 2; Rogerson et al, 2019; 2020; Chen et al, 2020; Ma et al, 2021; Pan et al, 2020). These events were already initiated after 1 day treatment (Supplementary Fig.…”